Jonathan Ledermann
MD
Emeritus Professor of Medical Oncology
👥Biography 个人简介
Jonathan Ledermann at University College London led the landmark ICON6 bevacizumab trial and the STUDY 19 olaparib maintenance trial that opened the PARP inhibitor era in ovarian cancer. His career of randomized trial leadership has established antiangiogenic and PARP inhibitor maintenance as cornerstones of ovarian cancer management. He was chair of the Gynecological Cancer Intergroup (GCIG) and has coordinated international cooperative group trials. His contributions have directly extended survival for ovarian cancer patients worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jonathan Ledermann 的研究动态
Follow Jonathan Ledermann's research updates
留下邮箱，当我们发布与 Jonathan Ledermann（University College London Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment